Background: Disease-modifying therapies benefit individuals with relapsing forms of multiple sclerosis, but their utility remains unclear for those without relapses. 1 not in disability progression. [2] [3] [4] [5] [6] In spite of their increasing prevalence as the MS population ages, 7 we know little about the efficacy of DMTs in older, non-ambulatory individuals because they are generally excluded from clinical trials.
Introduction
For over two decades, disease-modifying therapies (DMTs) have transformed treatment for relapsing forms of multiple sclerosis (MS). Clinical trials involving individuals with secondary progressive MS show reductions in relapse rates but, with few exceptions, 1 not in disability progression. [2] [3] [4] [5] [6] In spite of their increasing prevalence as the MS population ages, 7 we know little about the efficacy of DMTs in older, non-ambulatory individuals because they are generally excluded from clinical trials. Without evidence to guide them, clinicians remain divided on whether to initiate DMTs for individuals with secondary progressive MS without relapses or continue treatment started for relapsing-remitting MS after relapses have ceased. [14] [15] [16] [17] Faced with side effects and increasing prices, patients and families remain unsure about the costs versus benefits.
Given these complexities, we asked: 'What are the extent and predictors of DMT use in a representative sample of individuals with MS?' and 'What are consumer out-of-pocket (OOP) and total (payer) DMT costs?' Using data from the Sonya Slifka Longitudinal Multiple Sclerosis Study (Slifka), 18, 19 we hypothesized that real-world DMT prescribing practices would diverge from evidence-based guidelines and that use would be associated with income and health insurance status. Although this is a health services and not a clinical or treatment study, it raises the most fundamental question clinicians, patients, and families should ask themselves: 'Is DMT appropriate?'
Materials and methods

Data source
Initiated and funded by the NMSS, the Slifka Study collected data from 2000 to 2010. We recruited cohort 1 (N=2156) in 2000 and cohort 2 in 2007/ 2008 (N ¼ 2478) by randomly selecting participants from the NMSS mailing lists and conducting nationwide outreach for under-represented groups, i.e., recently diagnosed (within 12 months), ages 18-24 years, African-American, and Hispanic. We stratified by census region and rural and urban location, and used fractional sampling intervals to select systematic samples. 18 We confirmed diagnoses with participants' MS care providers or used proxy criteria (ever used a DMT and can report diagnosis date, course, and three typical MS symptoms). Comparison of cohort 1 to MS respondents in the National Health Interview Survey and the general population in the US Census demonstrated that participants generally represented the known demographic characteristics of the MS population. For the 2009 interview, we recruited all remaining cohort 1 and 2 participants achieving response rates of 62.5% and 41.4%, respectively, and a final sample of 2361.
We obtained institutional review board approval with waiver of written informed consent for community residents. At baseline, community residents provided verbal consent and nursing home residents signed written consent forms.
The Slifka computer-assisted telephone interviews used well-tested questions from federal surveys for sociodemographic characteristics; standard definitions of MS course, relapse, and progression; 20 
Estimating costs
To determine the average annual OOP cost, we multiplied participants' reported payments per prescription (standardized to a one-month supply) by the number of prescriptions or months of use if missing (adjusted for variation in recall periods).
Determining the average annual total cost to private and other payers is difficult because this information is not publicly available. However, Medicaid programs release retail transaction data for drugs, including quantities and total amounts paid to the pharmacy from any source. In 2009, Medicaid medication costs were similar to those of other payers because their reimbursements used comparable discounts off published list prices. 22 We therefore estimated the average annual total cost for each DMT by multiplying the number of prescriptions or months of use over patients' adjusted recall periods by the average price per prescription in the national Medicaid drug utilization files. 23 
Data analysis
We used data from the 2009 interview to determine the extent of DMT use overall and by drug, OOP and total costs, and significant differences in demographic and disease characteristics between users and nonusers (chi-squared tests). We identified predictors of DMT use and tested our hypothesis regarding the impact of income and health insurance status using two multivariable logistic regressions: model 1 with only disease characteristics and model 2 with additional sociodemographic attributes and insurance status. We report adjusted odds ratios (95% confidence intervals) and use P values less than 0.05 for statistical significance. Finally, for 2009, we show how total and OOP costs compared by course. Analyses excluded missing data, generally less than 1% of responses.
To explore our hypothesis regarding the impact of evidence-based guidelines on real-world DMT practice, we used previously published data from the 2000 Slifka interview. 19 We compared the percentage of individuals using DMTs in 2000 and 2009 by disease characteristics and age ([number users/number in subsample]*100), calculated changes in use rates from 2000 to 2009, and assessed whether user characteristics were consistent with evidence-based guidelines. Table 3 shows the multivariable models predicting DMT use. Adding sociodemographic characteristics (model 2) did not substantially change the adjusted odds ratios of use associated with disease characteristics (model 1). Participants with relapsing-remitting MS, non-ambulatory symptoms (e.g. sensory and bladder problems, fatigue), one to two relapses per year, shorter disease durations, or who needed a cane were significantly more likely to use DMTs than others. Significant sociodemographic characteristics associated with DMT use were aged less than 45 years and family income of US$100,000 or greater. Having health insurance increased the probability of use as did private coverage. (Table 5) . Forty-eight per cent of natalizumab users and 13.6-21.5% of other users had no OOP costs, mainly because of full coverage by their insurance, the Veteran's Health Administration or state or other programs (see Table 6 ). Similarly, without evidence of benefit for more disabled and older individuals, over one-third of participants requiring a wheeled mobility aid used DMTs and use increased by nearly 16% among individuals over the age of 54 years, the median onset for secondary progressive disease. 24 We cannot tell from these data whether older individuals 21 Based on free text responses from previous waves of Slifka study interviews, 'no MS symptoms' and 'completely bedridden' were added. 'Non-ambulatory symptoms' include 'sensory abnormalities', 'bladder impairment', 'incoordination', 'weakness', or 'fatigue' of any severity. 21 Based on free text responses from previous waves of Slifka study interviews, 'no MS symptoms' and 'completely bedridden' were added. 'Non-ambulatory symptoms' include 'sensory abnormalities', 'bladder impairment', 'incoordination', 'weakness', or 'fatigue' of any severity. e Total combined income before taxes of all family members and from all sources during previous calendar year, including money from jobs, net income from business, farm or rent, pensions, dividends, interest, social security, retirement income, disability insurance, unemployment payments, public assistance, etc. f Health insurance types: 'Private only' includes commercial, Tricare, American Association of Retired Persons, drug plans; 'Other public only' includes any public insurance except Medicare, i.e. Medicaid, General Medical Assistance, Veterans Health Administration, Indian Health Service, Workers Compensation, other government plan; 'Mixed coverage' includes any combination of private plus public insurance. AOR: adjusted odds ratio; CI: confidence interval.
Results
DMT use
with long disease durations and progressive disabling courses were continuing therapy started when younger, less disabled, and still having relapses, or whether treatment was initiated more recently. However, given evidence of declining DMT persistence among patients with longer duration and greater disability, our results are likely to reflect non-evidence-based initiation of DMT. 25 For medicine as a whole, non-adherence to evidence-based guidelines varies widely from 10% to 80%, 26, 27 and many explanations have been proposed. Unintentional deviations may reflect lack of knowledge, error, or uncritical reliance on others' opinions ('herding' behavior). 28 Intentional deviations, often valid, include contraindications, patient and physician preferences, absent or ambiguous cost-benefit data, and patient demographics. prescribe [DMTs] to patients with disability from progressive, nonrelapsing forms of MS' because there was no evidence of benefit that outweighed potential adverse effects and financial burden, particularly for those over aged 54 years and no longer ambulatory.
14 Implicit in this statement is the requirement of adequate evidence for a treatment recommendation and a recommendation to follow published guidelines.
Other MS experts responded that this was 'an oversimplified recommendation' because 'progressive patients who are on one of these agents and having no relapses are likely obtaining a partial treatment benefit and should remain on the agent'. 29 Implicit in this statement are two arguments. First, the 'absence of evidence is not evidence of absence', 30 i.e., lacking evidence of benefit does not mean there is no benefit, simply that more research is needed. Second, patients cannot wait until we have the data. The 'absence of evidence' argument may justify treatment when outcomes are truly unknown, but when welldesigned randomized clinical trials have been negative, the argument should be that further studies are required. Table 6 . Reasons for zero out-of-pocket costs for users of disease modifying therapies (DMTs) during recall period. Fortunately, a randomized clinical trial is underway on the safety of discontinuing DMTs in individuals aged 55 years and older without relapses or MRI changes, but data will not be available until at least 2021. 31 Meanwhile, the field wants to know 'What can we do now?' First, patients and clinicians can read the latest guidelines 32 and research, [33] [34] [35] [36] [37] [38] discuss reasons for departures, and reach a shared decision despite the discomfort of having little clear and compelling evidence. Second, the MS community can engage in 'unbiased discussion' 39, 40 that examines the full range of issues from patient and family preferences to societal costs due to increased healthcare expenditures, taking care not Table 2 ). b Unweighted percentage of users in sample or subgroup (number of users/number in sample or subgroup). Numerators are the number of users at time of interview (not over recall period as in Table 2 ). 21 Based on free text responses from previous waves of Slifka study interviews, 'no MS symptoms' and 'completely bedridden' were added. 'Non-ambulatory symptoms' include 'sensory abnormalities', 'bladder impairment', 'incoordination', 'weakness', or 'fatigue' of any severity. NA: category not included in 2000 interview.
to present opinion as fact and to recognize the communal context 28 and external influences on treatment decisions. The 2018 guideline development process is noteworthy for its inclusion of people with MS and public reviews and emphasis on patient-doctor communication: as such, it sets an example for discussing its recommendation that 'clinicians should assess the likelihood of future relapse' and 'may advise discontinuation of DMT in people with [secondary progressive MS] who do not have ongoing relapses (or . . . MRI activity) and have not been ambulatory . . . for at least 2 years. 32 Our study showed that annual total costs for first generation DMTs were three times higher in 2009 than in 2000. They have skyrocketed since then to over US$60,000, 41, 42 some even to US$86,000, 43 with annual increases seven times higher than average drug inflation. 44 We do not know, but should ask, whether use without evidence was contributory to the cost containment efforts discussed below. Escalating total costs inevitably increases the patient's share: even in 2009 some individuals reported extraordinary OOP spending.
Our observation that people with high incomes and health insurance were more likely to use DMTs almost certainly indicates that low income and inadequate coverage limited access to these medications, reflecting well-known causes of healthcare disparity. Even though expansion of Medicaid with the Affordable Care Act provides coverage to many previously uninsured patients, their DMT utilization is lower than among the commercially insured. 45 Use is also lower among those with high costsharing plans. 46 
Limitations
This study has limitations. First, the data do not include DMTs approved since 2009. However, a fundamental concern has not changed since 2000: in spite of clear and consistent guidelines, and no new evidence to the contrary, many patients are still newly prescribed or continued on DMTs without evidence of their effectiveness. Furthermore, from 2009 to 2014, injectable DMTs were still used by 93.7% of almost 9000 individuals with MS initiating and 60.6% of those switching DMTs. 47 Second, Slifka participants may not fully represent individuals with MS in the USA. Nevertheless, the sample includes patients receiving care in both academic and community settings and from MS specialists, general neurologists, and primary care physicians, thereby representing the full range of treatment practices. Because we followed participants over a critical nine-year period, from early adoption to established DMT use, we could show that prescribing DMTs for patients for whom there was no evidence of benefit continued in spite of consistent evidence-based guidelines.
Third, because information on private sector drug prices is unavailable, we had to rely on Medicaid payments to impute total DMT costs for patients mainly covered by private insurance and, without rebate information, we may have overestimated by an unknown amount. Still, Medicaid is the best available source of retail transaction costs, particularly for the years of our study. Because OOP costs were based on participants' daily records, they are reliable.
Despite these limitations, our results have important implications for the present and for future studies of DMT utilization. Our findings can serve as benchmarks as prices rise and payers intensify efforts to control costs, producing 'a cascade of negative effects' on patients and families. 44 A recent survey of 59 health plans revealed that 93% require prior authorization and 58% use step therapy for DMTs, 48 and formulary restrictions have been shown to affect adherence negatively. 49 The overutilization of DMTs by patients unlikely to benefit will heighten insurers' cost concerns and could lead to greater constraints on patient and clinician preferences. If patient-centered care is to become a certainty, decisions about DMT use ought to be driven by the evidence and further informed by the clinician's medical judgment and the patient's goals and values. Our data indicate that real-life decision-making is highly variable and that more evidence and education are needed to ensure the most appropriate treatments for the right individuals at the right time at the right cost.
Improving MS health outcomes and access to care while controlling escalating costs will require concerted efforts to adhere to the evidence-based guidelines we have now, while continually working to improve them, 26 study their implementation and acceptance, and remove barriers to prompt DMT initiation and equitable use. Guideline dissemination and education are essential, and should be free of pharmaceutical and payer influence.
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